Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253148 · ClinicalTrials.gov registry record · NA
Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT01253148 is a NA study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 25 participants.
The verdict
NCT01253148, a NA study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Therasphere will be a better way to treat cholangiocarcinoma. The investigators want to find out what effects, good and/or bad, this treatment will have on the patient and their cancer.
Interventions
- DEVICE TheraSphere® Yttrium-90 (Y-90) Microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01253148
The ClinicalTrials.gov registry entry for NCT01253148 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TheraSphere® Yttrium-90 (Y-90) Microspheres is the first listed.
NCT01253148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01253148 about?
NCT01253148 is a clinical study titled "Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma". The purpose of this study is to see if Therasphere will be a better way to treat cholangiocarcinoma. The investigators want to find out what effects, good and/or bad, this treatment will have on the patient and their cancer.
What is the current status of trial NCT01253148?
This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2011-01. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01253148?
The interventions under investigation include: TheraSphere® Yttrium-90 (Y-90) Microspheres (DEVICE).
Who is sponsoring clinical trial NCT01253148?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.